"Slow Start for 1st Drug in Slowing Alzheimer's Progression"

The first drug shown to slow Alzheimer’s disease, Leqembi, has had a slow start in the U.S. market, with lagging sales, delayed hospital adoption, and insurance coverage rejections. While offering hope for patients, the drug's limited impact and potential side effects have led to cautious uptake. Challenges include setting up systems for drug delivery, understanding coverage, and identifying eligible patients. Despite these hurdles, the drug's maker, Eisai, remains optimistic about its potential and is working on an injectable version and seeking approval for an easier-to-use form.